Phase 1 N=7 Pharmacodynamic Evaluation of Intranasal Nalmefene
Pharmacodynamic
Primary: Change in Minute Ventilation — 3.432; 5.744 L/min — p=<0.0009
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=36 Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran
Healthy
Primary: Total Dabigatran (Dabi): Area Under the Curve 0 to Infinity (AUC0-∞) — 281.05; 485.48; 410.46 ng*h/mL
Phase 4 N=34 A Pharmacodynamic Study With Ticagrelor in African American Patients
Stable Coronary Artery Disease
Primary: Inhibition of the P2Y12 Receptor as Measured by Platelet Reaction Unit (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading…
Phase 4 N=40 A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
Stable Coronary Artery Disease
Primary: Inhibition of the P2Y12 Receptor as Measured by P2Y12 Reactions Units (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading…
Phase 4 N=65 A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:
Coronary Artery Disease
Primary: Platelet Reactivity — 36; 33 PRU
Phase 2 N=23 Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
Stargardt Disease · Macular Atrophy
Primary: Change in Electrical Response of the Retina to a Flash of Light, as Measured by Electroretinogram — -12.23; 68.00; 96.69 percent suppression
N/A N=18 PharmacoMRI of Parkinson Disease
Parkinson's Disease
Primary: Correlation Coefficient Between UPDRS III Score and Independent Components Analysis Network Strength in Left Parietal Cortex. — 0.5869 unitless
Phase 4 N=82 Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies
Coronary Artery Disease · Peripheral Arterial Disease · Atrial Fibrillation
Primary: Platelet-Mediated Global Thrombogenicity — 66; 59; 69; 71 percentage of aggregation — p=0.275
Phase 2 N=100 Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia
Hypertriglyceridemia
Primary: Percent Change in Plasma Triglycerides (Pharmacodynamic Population) — -20.9; -18.3 Percent Change from baseline
N/A N=110 Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease
Coronary Artery Disease
Primary: Platelet Reactivity by Vasodilator-stimulated Phosphoprotein (VASP) — 32.1; 32.6 PRI%
Phase 1 N=23 Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change in Clearance of Sodium, Potassium, Creatinine, Magnesium, Chloride,Calcium, Phosphate and Uric Acid From Baseline — -0.031; -0.055; -0.071; 0.143 ml/min
Phase 4 N=110 Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease
Coronary Artery Disease
Primary: P2Y12 Reaction Units — 95.0; 49.0 PRU (P2Y12 Reaction Units)
Phase 2 N=20 Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects
Reflux
Primary: Reflux Episodes 0 to 3 Hours Post Meal — 15.1; 12.5; 11.0; 12.7 Episodes
Phase 1 N=72 Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors
Healthy Subjects · Pharmacokinetics · Pharmacodynamics
Primary: Baseline-adjusted Area Under Effect Curve (AUEC) for LDL-C for Evolocumab and Alirocumab — -380; -754; -866; -1832 mg/dL*day
Phase 1 N=11 Prescription Medication Interactions
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
N/A N=82 Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Coronary Artery Disease · Acute Coronary Syndrome
Primary: Platelet Reactivity Measured as P2Y12 Reaction Units (PRU) Determined by Verify Now-P2Y12 Assay — 45; 63 PRU
Phase 1 N=77 Pharmacodynamic Study of Cilostazol in Healthy Volunteers
Healthy
Primary: Ex-vivo Inhibition Of Platelet Aggregation (IPA) — 0.82; 1.21; 1.03; 4.42 ratio
Phase 2 N=155 Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Primary: Relative Bioavailability of Tiotropium With GSP304 in Comparison to SPIRIVA RESPIMAT 5 μg Based on CmaxSS — 4.10; 8.00; 21.80; 14.00 pg/mL
N/A N=50 Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes
Diabetes Mellitus · Coronary Artery Disease
Primary: P2Y12 Reaction Units — 83; 52 PRU — p=0.022
Phase 2 N=59 Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects
Intubated and Mechanically Ventilated Pediatric Subjects
Primary: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t) — 2681.332; 6460.576; 16992.540; 28531.864 picograms*hr/mL
Phase 1 N=20 A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Endpoint MMTT AUC(0-4h) for Plasma Glucose — 0.92; 0.98 h*nmol/L — p=0.02
N/A N=35 Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy
Coronary Artery Disease
Primary: TRAP-induced Platelet Aggregation — 74; 77 percentage of aggregation — p=<0.05
Phase 1 N=72 Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists
Healthy Subjects · Pharmacokinetics · Pharmacodynamics
Primary: Area Under Effect Curve (AUEC) for Eosinophils for Mepolizumab and Reslizumab — -1804; -195; -1456; -1428 Percentage change from baseline * day
Phase 2 N=37 Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199
Asthma · Airway Obstruction
Primary: FEV1 Peak Effect Within 0 - 24 h Post-dose — 3.56; 3.62; 3.70; 3.62 L
Phase 3 N=91 Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma
Mild Persistent Asthma
Primary: Post-dose PC20 Concentration After Receiving Differing Doses of Test, Reference, or Placebo — 0.608; 3.779; 4.432; 3.928 log(mg/mL) — p=<0.0001
Phase 4 N=77 Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
Coronary Artery Disease · Acute Coronary Syndrome
Primary: Platelet Reactivity Measured by VerifyNow — 23; 153; 65 PRU
Phase 4 N=36 Ticagrelor China Pharmacokinetic/Pharmacodynamic Study
Stable Coronary Heart Disease (CHD)
Primary: IPA on Day 1 — 27.09; 25.87; 33.34; 57.20 % IPA
Early Phase 1 N=6 Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer
Squamous Cell Carcinoma of the Oral Cavity
Primary: Area Under the Curve (AUC) for Matrine in Saliva — 4007.9 ng x h/mL
Phase 1 N=30 Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites
Epilepsy
Primary: Maximum Drug Concentration (Cmax) — 9469; 9867; 15067; 17309 ng/mL
N/A N=60 In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients
Coronary Artery Disease
Primary: Platelet Reactivity Index (PRI) Determined by Whole Blood Vasodilator-stimulated Phosphoprotein (VASP) — 30; 30; 18; 17 %PRI